查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1424050

皮下免疫球蛋白市場、份額、規模、趨勢、產業分析報告：按最終用途、地區和細分市場預測，2024-2032年

Subcutaneous Immunoglobulin Market Share, Size, Trends, Industry Analysis Report, By Application (Primary Immunodeficiency Disease, Secondary Immunodeficiency Disease); By End Use; By Region; Segment Forecast, 2024- 2032
出版日期: | 出版商: Polaris Market Research | 英文 118 Pages | 商品交期: 最快1-2個工作天內

價格

根據Polaris Market Research的最新研究，到2032年，全球皮下免疫球蛋白市場規模預計將達到330.2億美元。 該研究報告提供了對當前市場動態的詳細洞察，並對未來市場成長進行了分析。

由於適應症的擴大和治療用途的擴大，皮下免疫球蛋白市場正在創造利潤豐厚的機會。 皮下注射免疫球蛋白製劑不僅限於其在免疫缺陷疾病中的傳統用途，而且還被用於自體免疫疾病、神經病學和皮膚病學等領域。 研究顯示免疫球蛋白在慢性發炎性脫髓鞘性多發性神經病變 (CIDP)、重症肌無力和多灶性運動神經病變等疾病中的潛在用途正在推動其應用的增加。 皮下免疫球蛋白製劑的多功能性和患者友好的給藥方法使其成為各種醫療領域有前途的治療選擇，使市場多樣化並擴大適應症和治療領域，以滿足不斷變化的醫療保健環境。

兒科應用對於推動皮下免疫球蛋白市場機會至關重要。 皮下注射免疫球蛋白作為治療兒童免疫缺陷疾病的一種有前途的治療方法正在獲得認可，提供了一種侵入性較小且方便的選擇。 皮下注射可提高治療依從性，並滿足對兒科友善醫療保健解決方案不斷增長的需求。 它著重於兒科族群的有效性和安全性，並解決兒童免疫缺陷疾病日益流行的問題。

以患者為中心的醫療趨勢，尤其是針對免疫缺陷病等慢性疾病的趨勢，正在推動對家庭治療的需求。 這種方法提高了患者的舒適度和便利性，並減輕了醫療機構的負擔。 為患者和照護者提供易於使用的輸液設備和教育資源進一步支持家庭管理。 隨著醫療保健向分散模式發展，並且患者希望對自己的護理有更多的控制權，皮下免疫球蛋白市場反映了醫療保健服務不斷變化的格局，並致力於提供易於使用且有效的家庭解決方案，正在不斷成長。

製藥公司越來越多地瞄準發展中地區，在這些地區，皮下免疫球蛋白的便利性和可及性使其成為一種流行的治療方法。 這些新興市場不斷擴大的醫療基礎設施和對先進治療的認識不斷提高，為皮下免疫球蛋白的廣泛使用創造了有利的環境。 透過涵蓋服務不足的人群，該市場與提供有效的免疫缺陷治療的全球目標保持一致。 隨著這些地區醫療保健系統的進步，皮下免疫球蛋白市場處於有利位置，可以挖掘未開發的潛力，提供創新的解決方案，並推動這些充滿活力和不斷擴大的市場的成長。我就是。

皮下免疫球蛋白市場報告亮點

2023年，原發性免疫缺陷類別由於家庭給藥、全身副作用減少和患者滿意度提高而佔據了很大的市場份額。

2023年，醫院領域因其在免疫缺陷疾病、神經系統疾病和自體免疫疾病方面的應用而佔據了很大的銷售份額。

2023 年，由於患者意識的提高、醫療保健支出的增加以及以患者為中心的醫療，北美地區主導了全球市場。

由於生物產品實驗室、Biotest AG、CSL Behring、Grifols、Laboratoire francais du Fractionnement et des Biotechnologies、Octapharma 和 Takeda Pharmaceutical Company 等具有全球影響力的市場參與者的存在，市場競爭非常激烈。

目錄

第 1 章簡介

第 2 章執行摘要

第 3 章研究方法

第 4 章全球皮下免疫球蛋白市場洞察

  • 皮下免疫球蛋白市場 - 產業概況
  • 皮下免疫球蛋白市場動態
    • 促進因素和機會
      • 免疫缺陷疾病發生率的增加預計將刺激對該產品的需求
      • 以患者為中心的方法預計將推動市場成長
    • 抑制因素和挑戰
      • 高昂的處理成本可能會阻礙市場成長
  • PESTLE分析
  • 皮下免疫球蛋白產業的趨勢
  • 價值鏈分析
  • COVID-19 感染的影響分析

第 5 章全球皮下免疫球蛋白市場（依應用）

  • 主要發現
  • 簡介
  • 原發性免疫缺陷
  • 繼發性免疫缺陷

第 6 章全球皮下免疫球蛋白市場（依最終用途）

  • 主要發現
  • 簡介
  • 診所
  • 醫院
  • 居家護理
  • 其他

第 7 章按地區劃分的全球皮下免疫球蛋白市場

  • 主要發現
  • 簡介
    • 2019-2032 年皮下免疫球蛋白市場評估（按地區）
  • 皮下免疫球蛋白市場 - 北美
    • 北美：皮下免疫球蛋白市場，依最終用途，2019-2032 年
    • 北美：皮下免疫球蛋白市場，按應用劃分，2019-2032 年
    • 皮下免疫球蛋白市場－美國
    • 皮下免疫球蛋白市場 - 加拿大
  • 皮下免疫球蛋白市場 - 歐洲
    • 歐洲：皮下免疫球蛋白市場，依最終用途，2019-2032 年
    • 歐洲：皮下免疫球蛋白市場，依應用劃分，2019-2032 年
    • 皮下免疫球蛋白市場 - 英國
    • 皮下免疫球蛋白市場 - 法國
    • 皮下免疫球蛋白市場 - 德國
    • 皮下免疫球蛋白市場 - 義大利
    • 皮下免疫球蛋白市場 - 西班牙
    • 皮下免疫球蛋白市場 - 荷蘭
    • 皮下免疫球蛋白市場 - 俄羅斯
  • 皮下免疫球蛋白市場 - 亞太地區
    • 亞太地區：皮下免疫球蛋白市場，依最終用途，2019-2032 年
    • 亞太地區：皮下免疫球蛋白市場，依應用劃分，2019-2032 年
    • 皮下免疫球蛋白市場 - 中國
    • 皮下免疫球蛋白市場 - 印度
    • 皮下免疫球蛋白市場 - 馬來西亞
    • 皮下免疫球蛋白市場 - 日本
    • 皮下免疫球蛋白市場 - 印尼
    • 皮下免疫球蛋白市場 - 韓國
  • 皮下免疫球蛋白市場 - 中東和非洲
    • 中東和非洲：皮下免疫球蛋白市場，以最終用途，2019-2032 年
    • 中東和非洲：皮下免疫球蛋白市場，按應用劃分，2019-2032 年
    • 皮下免疫球蛋白市場 - 沙烏地阿拉伯
    • 皮下免疫球蛋白市場 - 阿拉伯聯合大公國
    • 皮下免疫球蛋白市場 - 以色列
    • 皮下免疫球蛋白市場 - 南非
  • 皮下免疫球蛋白市場 - 拉丁美洲
    • 拉丁美洲：皮下免疫球蛋白市場，依最終用途，2019-2032 年
    • 拉丁美洲：皮下免疫球蛋白市場，按應用劃分，2019-2032 年
    • 皮下免疫球蛋白市場 - 墨西哥
    • 皮下免疫球蛋白市場 - 巴西
    • 皮下免疫球蛋白市場 - 阿根廷

第 8 章競爭態勢

  • 擴張與收購分析
    • 擴大
    • 收購
  • 夥伴關係/協作/協議/揭露

第 9 章公司簡介

  • ADMA Biologics
  • Bio Product Laboratory
  • Biotest AG
  • China Biologic Products Holdings, Inc.
  • CSL Behring
  • Emergent BioSolutions
  • Grifols
  • Hansa Biopharma
  • InVivo Biotech Services
  • Kedrion Biopharma
  • Kamada Ltd.
  • Laboratoire francais du Fractionnement et des Biotechnologies
  • Octapharma
  • Shenzhen Weiguang Biological Products Co., Ltd.
  • Takeda Pharmaceutical Company
Product Code: PM4416

The global Subcutaneous Immunoglobulin market size is expected to reach USD 33.02 billion by 2032, according to a new study by Polaris Market Research. The report "Subcutaneous Immunoglobulin Market Share, Size, Trends, Industry Analysis Report, By Application (Primary Immunodeficiency Disease, Secondary Immunodeficiency Disease); By End Use; By Region; Segment Forecast, 2024- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Expanded indications and therapeutic applications are creating lucrative opportunities in the subcutaneous immunoglobulin market. Beyond its traditional use in immunodeficiency disorders, it is gaining traction in autoimmune diseases, neurology, and dermatology. Research showcasing its potential benefits in conditions like chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis, and multifocal motor neuropathy is driving increased adoption. The versatility and patient-friendly administration of subcutaneous immunoglobulin position it as a promising therapeutic option across diverse medical domains, diversifying the market and responding to the evolving healthcare landscape with expanded indications and therapeutic areas.

Pediatric applications are crucial in driving opportunities within the subcutaneous immunoglobulin market. Subcutaneous immunoglobulin is gaining traction as a promising treatment for immunodeficiency disorders in children, offering a less invasive and more convenient alternative. The subcutaneous administration method enhances treatment adherence, meeting the growing demand for child-friendly healthcare solutions. With a focus on efficacy and safety for the pediatric population, it addresses the rising prevalence of immunodeficiency disorders in children.

The trend towards patient-centric care, particularly for chronic conditions like immunodeficiency disorders, has intensified the demand for home-based administration. This approach enhances patient comfort and convenience and reduces the strain on healthcare facilities. The availability of user-friendly infusion devices and educational resources for patients and caregivers further supports home-based administration. As healthcare evolves towards decentralized models and patients desire more control over their treatment, the subcutaneous immunoglobulin market is growing by offering accessible and effective home-based solutions, reflecting the shifting landscape of healthcare delivery.

Pharmaceutical companies are increasingly targeting developing regions, where subcutaneous immunoglobulin's convenience and accessibility make it a sought-after treatment. Expanding healthcare infrastructure and growing awareness of advanced therapies in these emerging markets create a conducive environment for subcutaneous immunoglobulin adoption. By reaching underserved populations, the market aligns with the global goal of providing effective immunodeficiency disorder therapies. As healthcare systems in these regions advance, the subcutaneous immunoglobulin market is well-positioned to capitalize on the untapped potential, offering innovative solutions and fostering growth in these dynamic and expanding markets.

Subcutaneous Immunoglobulin Market Report Highlights

In 2023, the primary immunodeficiency disease segment accounted for significant market share owing to home-based administration, reduced systemic side effects, and improved patient satisfaction.

In 2023, the hospital segment held significant revenue share owing to application in immunodeficiency disorders, neurological conditions, and autoimmune disorders.

In 2023, North America region dominated the global market due to increasing patient awareness, rising healthcare expenditure, and patient-centric care.

The market is highly competitive owing to the existence of market players with a global presence, including Bio Product Laboratory, Biotest AG, CSL Behring, Grifols, Laboratoire francais du Fractionnement et des Biotechnologies, Octapharma, and Takeda Pharmaceutical Company among others.

Polaris Market Research has segmented the Subcutaneous Immunoglobulin market report based on application, end use, and region:

Subcutaneous Immunoglobulin, Application Outlook (Revenue - USD Billion, 2019 - 2032)

  • Primary Immunodeficiency Disease
  • Secondary Immunodeficiency Disease

Subcutaneous Immunoglobulin, End Use Outlook (Revenue - USD Billion, 2019 - 2032)

  • Clinics
  • Hospitals
  • Homecare
  • Others

Subcutaneous Immunoglobulin, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • France
  • Germany
  • UK
  • Italy
  • Netherlands
  • Spain
  • Russia
  • Asia Pacific
  • Japan
  • China
  • India
  • Malaysia
  • Indonesia
  • South Korea
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Subcutaneous Immunoglobulin Market Insights

  • 4.1. Subcutaneous Immunoglobulin Market - Industry Snapshot
  • 4.2. Subcutaneous Immunoglobulin Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing incidence of immunodeficiency disorders is projected to spur the product demand
      • 4.2.1.2. Patient-centric approach is expected to drive market growth
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost of treatment is likely to impede the market growth
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Subcutaneous Immunoglobulin Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Subcutaneous Immunoglobulin Market, by Application

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Subcutaneous Immunoglobulin, by Application, 2019-2032 (USD Billion)
  • 5.3. Primary Immunodeficiency Disease
    • 5.3.1. Global Subcutaneous Immunoglobulin Market, by Primary Immunodeficiency Disease, by Region, 2019-2032 (USD Billion)
  • 5.4. Secondary Immunodeficiency Disease
    • 5.4.1. Global Subcutaneous Immunoglobulin Market, by Secondary Immunodeficiency Disease, by Region, 2019-2032 (USD Billion)

6. Global Subcutaneous Immunoglobulin Market, by End Use

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • 6.3. Clinics
    • 6.3.1. Global Subcutaneous Immunoglobulin Market, by Clinics, by Region, 2019-2032 (USD Billion)
  • 6.4. Hospitals
    • 6.4.1. Global Subcutaneous Immunoglobulin Market, by Hospitals, by Region, 2019-2032 (USD Billion)
  • 6.5. Homecare
    • 6.5.1. Global Subcutaneous Immunoglobulin Market, by Homecare, by Region, 2019-2032 (USD Billion)
  • 6.6. Others
    • 6.6.1. Global Subcutaneous Immunoglobulin Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Subcutaneous Immunoglobulin Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Subcutaneous Immunoglobulin Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 7.3. Subcutaneous Immunoglobulin Market - North America
    • 7.3.1. North America: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
    • 7.3.2. North America: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.3.3. Subcutaneous Immunoglobulin Market - U.S.
      • 7.3.3.1. U.S.: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.3.3.2. U.S.: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.3.4. Subcutaneous Immunoglobulin Market - Canada
      • 7.3.4.1. Canada: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.3.4.2. Canada: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • 7.4. Subcutaneous Immunoglobulin Market - Europe
    • 7.4.1. Europe: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
    • 7.4.2. Europe: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.4.3. Subcutaneous Immunoglobulin Market - UK
      • 7.4.3.1. UK: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.4.3.2. UK: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.4.4. Subcutaneous Immunoglobulin Market - France
      • 7.4.4.1. France: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.4.4.2. France: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.4.5. Subcutaneous Immunoglobulin Market - Germany
      • 7.4.5.1. Germany: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.4.5.2. Germany: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.4.6. Subcutaneous Immunoglobulin Market - Italy
      • 7.4.6.1. Italy: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.4.6.2. Italy: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.4.7. Subcutaneous Immunoglobulin Market - Spain
      • 7.4.7.1. Spain: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.4.7.2. Spain: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.4.8. Subcutaneous Immunoglobulin Market - Netherlands
      • 7.4.8.1. Netherlands: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.4.8.2. Netherlands: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.4.9. Subcutaneous Immunoglobulin Market - Russia
      • 7.4.9.1. Russia: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.4.9.2. Russia: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • 7.5. Subcutaneous Immunoglobulin Market - Asia Pacific
    • 7.5.1. Asia Pacific: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
    • 7.5.2. Asia Pacific: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.5.3. Subcutaneous Immunoglobulin Market - China
      • 7.5.3.1. China: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.5.3.2. China: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.5.4. Subcutaneous Immunoglobulin Market - India
      • 7.5.4.1. India: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.5.4.2. India: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.5.5. Subcutaneous Immunoglobulin Market - Malaysia
      • 7.5.5.1. Malaysia: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.5.5.2. Malaysia: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.5.6. Subcutaneous Immunoglobulin Market - Japan
      • 7.5.6.1. Japan: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.5.6.2. Japan: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.5.7. Subcutaneous Immunoglobulin Market - Indonesia
      • 7.5.7.1. Indonesia: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.5.7.2. Indonesia: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.5.8. Subcutaneous Immunoglobulin Market - South Korea
      • 7.5.8.1. South Korea: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.5.8.2. South Korea: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • 7.6. Subcutaneous Immunoglobulin Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
    • 7.6.2. Middle East & Africa: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.6.3. Subcutaneous Immunoglobulin Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.6.4. Subcutaneous Immunoglobulin Market - UAE
      • 7.6.4.1. UAE: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.6.4.2. UAE: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.6.5. Subcutaneous Immunoglobulin Market - Israel
      • 7.6.5.1. Israel: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.6.5.2. Israel: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.6.6. Subcutaneous Immunoglobulin Market - South Africa
      • 7.6.6.1. South Africa: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.6.6.2. South Africa: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • 7.7. Subcutaneous Immunoglobulin Market - Latin America
    • 7.7.1. Latin America: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
    • 7.7.2. Latin America: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.7.3. Subcutaneous Immunoglobulin Market - Mexico
      • 7.7.3.1. Mexico: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.7.3.2. Mexico: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.7.4. Subcutaneous Immunoglobulin Market - Brazil
      • 7.7.4.1. Brazil: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.7.4.2. Brazil: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.7.5. Subcutaneous Immunoglobulin Market - Argentina
      • 7.7.5.1. Argentina: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.7.5.2. Argentina: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. ADMA Biologics
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Bio Product Laboratory
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Biotest AG
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. China Biologic Products Holdings, Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. CSL Behring
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6.Emergent BioSolutions
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Grifols
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Hansa Biopharma
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. InVivo Biotech Services
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Kedrion Biopharma
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Kamada Ltd.
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. Laboratoire francais du Fractionnement et des Biotechnologies
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development
  • 9.13. Octapharma
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Development
  • 9.14. Shenzhen Weiguang Biological Products Co., Ltd.
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Development
  • 9.15. Takeda Pharmaceutical Company
    • 9.15.1. Company Overview
    • 9.15.2. Financial Performance
    • 9.15.3. Product Benchmarking
    • 9.15.4. Recent Development

List of Tables

  • Table 1 Global Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 2 Global Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 3 Subcutaneous Immunoglobulin Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 4 North America: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 5 North America: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 6 U.S.: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 7 U.S.: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 8 Canada: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 9 Canada: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 10 Europe: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 11 Europe: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 12 UK: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 13 UK: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 14 France: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 15 France: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 16 Germany: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 17 Germany: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 18 Italy: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 19 Italy: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 20 Spain: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 21 Spain: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 22 Netherlands: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 23 Netherlands: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 24 Russia: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 25 Russia: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 26 Asia Pacific: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 27 Asia Pacific: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 28 China: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 29 China: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 30 India: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 31 India: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 32 Malaysia: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 33 Malaysia: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 34 Japan: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 35 Japan: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 36 Indonesia: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 37 Indonesia: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 38 South Korea: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 39 South Korea: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 40 Middle East & Africa: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 41 Middle East & Africa: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 42 Saudi Arabia: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 43 Saudi Arabia: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 44 UAE: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 45 UAE: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 46 Israel: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 47 Israel: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 48 South Africa: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 49 South Africa: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 50 Latin America: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 51 Latin America: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 52 Mexico: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 53 Mexico: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 54 Brazil: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 55 Brazil: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 56 Argentina: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 57 Argentina: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)

List of Figures

  • Figure 1 Global Subcutaneous Immunoglobulin Market, 2019-2032 (USD Billion)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by End Use
  • Figure 7 Global Subcutaneous Immunoglobulin Market, by End Use, 2022 & 2032 (USD Billion)
  • Figure 8 Market by Application
  • Figure 9 Global Subcutaneous Immunoglobulin Market, by Application, 2022 & 2032 (USD Billion)
  • Figure 10 Subcutaneous Immunoglobulin Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 11 Strategic Analysis - Subcutaneous Immunoglobulin Market